Aardvark Antique Mall is the kind of place where you can literally lose yourself for hours. And I mean literally. Bring ...

Aardvark Antique Mall attracts a diverse crowd, from serious collectors to casual browsers, from hipsters looking for ironic ...

Some small IPOs are tentatively scheduled for the short holiday week ahead. Space and defense contractor Karman Holdings ...

Cybersecurity company SailPoint opened for trading on Thursday, returning to the markets more than two years after it went private.Maximize ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following a $94M initial public offering. Read more here.

Aardvark Therapeutics Inc. made its public market debut Thursday, securing $94 million in its initial public offering (IPO).

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

The syndicate led by Morgan Stanley, Goldman Sachs, JP Morgan and Evercore closed the books north of 20x covered on the back of strong long-only/mutual fund demand and a 100% hit rate in investor ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Aardvark Therapeutics, Inc. ("Aardvark") (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...

Clinical-stage biopharmaceutical company Aardvark Therapeutics (AARD) priced its IPO of ~5.89M shares at $16.00 per share. All of the shares are being offered by Aardvark. The California-based startup ...